ArticleBMC public health2024
Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives.
Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Drivers and barriers to influenza vaccination in the post-COVID-19 era in the Federation of Bosnia and Herzegovina: A qualitative study using focus groups with risk groups and in-depth interviews with physicians.Human vaccines & immunotherapeutics · 2026Article
- Influenza vaccine Hesitancy in older adults in China: A latent profile analysis.Human vaccines & immunotherapeutics · 2026Article
- Live Attenuated Influenza Vaccine (LAIV) for Children for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis.Infectious diseases and therapy · 2026Article
- Evaluating influenza-related short videos on Chinese platforms: information quality, user engagement, and public health implications.NPJ primary care respiratory medicine · 2026Article
- A reversible broad-spectrum antiviral targets the human V-ATPase VResearch square · 2026Article
- Influenza Vaccination in Spain: Understanding the Impact of Suboptimal Coverage on Health, Society, and the Economy.Vaccines · 2026Review
- Effectiveness of Influenza Vaccines in Italy in the 2024/2025 Season: A Nationwide, Test-Negative Design Study Based on Surveillance Records.Influenza and other respiratory viruses · 2026Review
- Global burden of influenza lower respiratory tract infections in children younger than 5 years from 1990 to 2021.Journal of thoracic disease · 2026Article
- Attitudes and behaviors of adolescents with asthma and their parents toward influenza and COVID-19 vaccination: barriers and facilitators of uptake.BMC pediatrics · 2026Article
- Review
- Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Article
- Risk and resilience factors associated with the progression of influenza to severe disease outcomes: umbrella review protocol.BMJ open · 2025Article
- Seasonality of Influenza and Optimizing Timing of Vaccination: Systematic Review and Meta-Analysis.Cureus · 2025Review
- Attitudes Toward COVID-19 and Seasonal Influenza Vaccines in the Post-COVID Era: A Cross-Sectional Study Among Adults in Malta.Pharmacy (Basel, Switzerland) · 2025Article
- Cost-Effectiveness Analysis of Expanding Influenza Vaccination to Adults Aged 50 and Over in France.Infectious diseases and therapy · 2025Article
- Review
- Bid Protein: A Participant in the Apoptotic Network with Roles in Viral Infections.International journal of molecular sciences · 2025Review
- A thematic analysis of flu vaccine hesitance in ethnically minoritised communities in Liverpool.PloS one · 2025Article
- Immunogenicity of one dose and two doses of adjuvanted influenza vaccine in lung transplant candidates.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeasonal influenza epidemics have a substantial public health and economic burden, which can be alleviated through vaccination. The World Health Organization (WHO) recommends a 75% vaccination coverage rate (VCR) in: older adults (aged ≥ 65 years), individuals with chronic conditions, pregnant women, children aged 6-24 months and healthcare workers. However, no European country achieves this target in all risk groups. In this study, potential public health and economic benefits achieved by reaching 75% influenza VCR was estimated in risk groups across four European countries: France, Italy, Spain, and the UK.
methodsA static epidemiological model was used to estimate the averted public health and economic burden of increasing the 2021/2022 season VCR to 75%, using the efficacy data of standard-dose quadrivalent influenza vaccine. For each country and risk group, the most recent data on population size, VCR, pre-pandemic influenza epidemiology, direct medical costs and absenteeism were identified through a systematic literature review, supplemented by manual searching. Outcomes were: averted influenza cases, general practitioner (GP) visits, hospitalisations, case fatalities, number of days of work lost, direct medical costs and absenteeism-related costs.
resultsAs of the 2021/2022 season, the UK achieved the highest weighted VCR across risk groups (65%), followed by Spain (47%), France (44%) and Italy (44%). Based on modelling, the 2021/2022 VCR prevented an estimated 1.9 million influenza cases, avoiding 375,200 GP visits, 73,200 hospitalisations and 38,400 deaths. To achieve the WHO 75% VCR target, an additional 24 million at-risk individuals would need to be vaccinated, most of which being older adults and patients with chronic conditions. It was estimated that this could avoid a further 918,200 influenza cases, 332,000 GP visits, 16,300 hospitalisations and 6,300 deaths across the four countries, with older adults accounting for 52% of hospitalisations and 80% of deaths. An additional €84 million in direct medical costs and €79 million in absenteeism costs would be saved in total, with most economic benefits delivered in France.
conclusionsOlder adults represent most vaccine-preventable influenza cases and deaths, followed by individuals with chronic conditions. Health authorities should prioritise vaccinating these populations for maximum public health and economic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.